Archive for May, 2014

Charlottesville, VA (PRWEB) May 27, 2014

Researchers at the University of Virginia School of Medicine have devised a way to detect unintended side effects of manipulating genes using a revolutionary new system that is sweeping the scientific world by storm.

The gene targeting system, called CRISPR, allows editing of genetic information at specifically targeted sites in the genome. UVAs new approach reveals the system has the potential to bind to unintended sites and cause gene mutations at some of these sites mutations that could have serious consequences for research and efforts to develop medical treatments. UVAs new approach, however, also identifies ways to help prevent those potentially dangerous off-target effects, allowing scientists to improve their results with this important new gene-editing system.

A primary goal of gene manipulation is to correct harmful mutations, so it is vital to avoid introducing mutations unintentionally, explained UVAs Mazhar Adli, PhD, of the Department of Biochemistry and Molecular Genetics. We know that genetic mutations are hallmarks of disease. The whole aim is to change these apparent genetic mutations, to go and correct these mutations, he said. We want to change this information only at the targeted space, at the targeted locus. If you change any other information, basically you are introducing mutations that you dont want. You are correcting one gene and potentially you might be introducing mutations in 10 other genes and maybe many other places in the genome.

Adlis new research sheds light on the potential off-target effects of the CRISPR/Cas9 gene editing system. The system has proved extremely popular because it allows scientists to manipulate specific sections of the genome of living mammals, making it a tool of tremendous importance for scientific research. It has been adopted quickly and widely, including for work in human cells, because it is comparatively simple and because many labs have the resources to use it. You can basically target any genomic region in living cells and change the genetic information, which has been the holy grail of research for the past several decades, Adli said. To be able to go and change the genetic information in living cells was a dream, basically.

UVAs new research helps explain the mechanism that underpins the CRISPR system and why it is vulnerable to off-target gene mutations. We not only found where it binds in the genome, we also investigated why it goes to these regions in the genome. By analyzing specific sequences underlying these off-targets, we also found out the determinants why it goes to the on-targets and also to these off-target regions, and our research shows that it goes there because of some sequence similarity to the original targeted regions, Adli said. So our results will help improve the specificity of the system so that we can minimize the off-targets.

Adlis work also showed that the naturally occurring form of a key enzyme used in the CRISPR system introduces far more mutations than an altered form of that enzyme that is less commonly used. The former cuts both strands of DNA during gene editing, allowing mutations to occur, while the latter snips only one strand, allowing cells to repair the damage without introducing mutations.

Unfortunately the wild-type form [the naturally occurring form] is much easier to deal with. Everyone in the field is using the wild type. Now with this paper, and with additional papers coming out, they will have to stop using the wild type form of the enzyme. They have to use the [altered form] to overcome the off-targets. It is much superior and the off-targets are very dangerous.

The findings have been published online by the journal Nature Biotechnology and will appear in a forthcoming print edition. The paper was authored by UVAs Cem Kuscu and Sevki Arslan, sharing credit as the lead authors; Ritambhara Singh; Jeremy Thorpe; and Adli.

Go here to read the rest:
UVA Detects Unwanted Effects of Important Gene Manipulation System

A "life-saving" programme of tests for an inherited high cholesterol condition has been launched across the UK with 1 million of funding from the British Heart Foundation.

New tests aim to identify families whose members carry the gene for familial hypercholesterolaemia

The aim is to identify the one in 200 families whose members carry the gene for familial hypercholesterolaemia (FH), which can cut decades off a person's life.

Undiagnosed FH leaves individuals at high risk of developing heart disease and dying suddenly at a young age from a heart attack.

On average, the untreated condition shortens life expectancy by 20 to 30 years. But if spotted early, treatment with cholesterol-lowering statin drugs, lifestyle advice and careful monitoring can allow people with FH to live as long as anyone else.

FH is caused by a faulty gene that raises levels of the harmful form of cholesterol, low-density lipoprotein (LDL) from birth. At least 85% of those affected by the condition are undiagnosed.

The new scheme involves specialist nurses carrying out simple DNA blood tests to see if individuals with symptoms of high cholesterol carry the FH gene.

If the gene is discovered, other family members are then referred for "cascade" testing.

Steve Humphries, British Heart Foundation (BHF) professor of cardiovascular genetics at University College London, said: "With an estimated one in 200 hundred families carrying an FH-causing faulty gene in the UK, the introduction of cascade testing represents a huge opportunity to identify and treat people before they suffer from potentially life-threatening heart problems.

"After so many years of carrying out the laboratory research on FH, I am delighted now to see genetic testing being rolled out nationwide. But with such a high number of people remaining undiagnosed there is still more to be done if we're to get a complete picture of how FH affects the UK population."

Link:
Tests for cholesterol gene start

04 Genetic Engineering cont

By: tawkaw OpenCourseWare

See the original post:
04 Genetic Engineering cont - Video

03 Genetic Engineering

By: tawkaw OpenCourseWare

Read more here:
03 Genetic Engineering - Video

PUBLIC RELEASE DATE:

27-May-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 27, 2014The commonly used food additive monosodium glutamate (MSG) has been linked to obesity and disorders associated with the metabolic syndrome including progressive liver disease. A new study that identifies MSG as a critical factor in the initiation of obesity and shows that a restrictive diet cannot counteract this effect but can slow the progression of related liver disease is published in Journal of Medicinal Food, a peer-reviewed journal from Mary Ann Liebert, Inc.. The paper is available on the Journal of Medicinal Food website.

Makoto Fujimoto and a team of international researchers from Japan, the U.S., and Italy monitored the weight gain and development of nonalcoholic fatty liver disease and its progression to nonalcoholic steatohepatitis in MSG-treated mice fed either a calorie-restricted or regular diet. They report their findings in the article "A Dietary Restriction Influences the Progression But Not the Initiation of MSG-Induced Nonalcoholic Steatohepatitis".

"Although MSG has been deemed a safe food additive, its dosage, interaction with other drugs, effects on vulnerable populations, and effects on chronic inflammatory diseases and neurological diseases are unknown," says Co-Editor-in-Chief Sampath Parthasarathy, MBA, PhD, Florida Hospital Chair in Cardiovascular Sciences, University of Central Florida, Orlando, in the Editorial "How Safe is Monosodium Glutamate? Exploring the Link to Obesity, Metabolic Disorders, and Inflammatory Disease" . The findings by Fujimoto et al. "may have far reaching implications, as childhood obesity is a major problem across the globe."

###

About the Journal

Journal of Medicinal Food is an authoritative, peer-reviewed, multidisciplinary journal published monthly in print and online. Led by Editors-in-Chief Sampath Parthasarathy, MBA, PhD, and Young-Eun Lee, PhD, Wonkwang University, Jeonbuk, Korea, this scientific journal for leaders of the nutraceutical and functional foods revolution publishes original scientific research on the bioactive substances of functional and medicinal foods, nutraceuticals, herbal substances, and other natural products. The Journal explores the chemistry and biochemistry of these substances, as well as the methods for their extraction and analysis, the use of biomarkers and other methods to assay their biological roles, and the development of bioactive substances for commercial use. Tables of content and a free sample issue may be viewed on the Journal of Medicinal Food website.

About the Publisher

Go here to read the rest:
What what role does MSG play in obesity and fatty liver disease?

Genetically modified organisms (also called GE for genetic engineering), are plants or animals created through the gene splicing techniques of biotechnology. They take fish genes (DNA), for example, and inject them into the tomatos DNA.

Most modified foods have been grown to resist chemicals, pests or disease. Thats all fine in theory, but a growing body of evidence connects GMOs with health problems, environmental damage, and more.

Of course Monsanto and other biotech companies say GE foods are safe to eat. Promises of increased yields, drought tolerance, enhanced nutrition, or any other consumer benefit have all proved false since they started doing this in the 1990s.

Most developed nations do not consider GMOs to be safe. In more than 50 countries around the world, including Australia, Japan, China, India and all of the European Union countries, there are significant restrictions or outright bans on the production and sale of GMOs. But here in the U.S., our government has approved GMOs based on studies conducted by the same corporations that created them and profit from their sale!

If theres no risk in eating products that contain GMOs then there should be no problem labeling them.

By supporting labeling, companies would say, Theres no risk, we have nothing to hide, says David Ropeik, creator and director of Improving Media Coverage of Risk.

We have the right to know how our food is grown. More people are realizing that the food they eat directly affects their health.

Vote YES for labeling of GMOs! Go to http://www.nongmoproject.org for more info.

TANYA OSTERSON

Coeur dAlene

Continued here:
GMOs: Dont be confused

President Barack Obama quizzed students on their robots, electric cars, genetic discoveries and other projects at the White House science fair, highlighting the administrations push to boost science, technology, engineering and matheducation.

U.S. companies have lamented a shortfall of workers trained in so-called STEM fields, and the government officials want to boost enrollment in such programs.

These are the fields of the future, Mr.Obama said.This is where the good jobs are going to be.

As part of the fair, Mr. Obama announced $35 million in Department of Education grants to support training of more science, engineering and math teachers, an expansion of the AmeriCorps STEM program and a mentoring plan to link tech workers with students.

The White House said 100 students from more than 30 states came to the fair.On the same day of a major announcement about Afghanistan, a call with Ukraines president-elect and developments in policy toward Syria, the president spent more than an hour visiting with some of the students and asking them about award-winning projects.

Were so proud of you, Mr. Obama told 18-year-oldElana Simonof New York City. Ms. Simon, who survived a rare form of liver cancer, discovered a link between a common genetic mutation and the illness.

Peyton Robertson, a 12-year-old from Fort Lauderdale, Fla., developed a sandless sandbag to help protect against flooding. When dry, my bags are really lightweight, they weigh only four pounds, Mr. Robertson told the president. But then when you add water it expands and becomes heavy, it weighs 30 pounds.

Some tweets from the event:

See more here:
Obama Quizzes Kid Geniuses at White House Science Fair

PUBLIC RELEASE DATE:

27-May-2014

Contact: Shawna Williams shawna@jhmi.edu 410-955-8236 Johns Hopkins Medicine

A genetic variant linked to sudden cardiac death leads to protein overproduction in heart cells, Johns Hopkins scientists report. Unlike many known disease-linked variants, this one lies not in a gene but in so-called noncoding DNA, a growing focus of disease research. The discovery, reported in the June 5 issue of The American Journal of Human Genetics, also adds to scientific understanding of the causes of sudden cardiac death and of possible ways to prevent it, the researchers say.

"Traditionally, geneticists have studied gene variants that cause disease by producing an abnormal protein," says Aravinda Chakravarti, Ph.D., a professor of medicine, pediatrics, molecular biology and genetics, and biostatistics in the McKusick-Nathans Institute of Genetic Medicine at the Johns Hopkins University School of Medicine. "We think there will turn out to be many DNA variants that, like this one, cause disease by making too much or too little of a normal protein."

Chakravarti's interest in sudden cardiac death emerged a decade ago, when it claimed several of his colleagues within a few months. An expert in complex common diseases, he and his team knew that sudden cardiac death can be caused by many conditions. They focused on one: abnormalities in what is known as cardiac repolarization the time it takes for the heart to gear up to beat again.

The team compared the genetic sequences of tens of thousands of people with their electrocardiogram (ECG) results, identifying several regions on the genome with genetic variations associated with lengthened QT interval, a measure of cardiac repolarization, in the ECG. "The problem is that most of these variants lie outside of genes, in the noncoding DNA that controls how genes are used," Chakravarti says, "so it's hard to tell what genes they're affecting."

Despite the challenge, Chakravarti and his colleagues were able to home in on one suspect region of the genome housing a gene called NOS1AP. "There were many variants grouped in this area," says Ashish Kapoor, Ph.D., a postdoctoral researcher in Chakravarti's laboratory, "so we catalogued all 200 that we found." The team then went through a process of elimination using genetically engineered, lab-grown cells and zebra fish to identify a variant in the noncoding DNA that affected how much protein was made by the nearby NOS1AP gene.

Next, they cultured rat heart cells and engineered them to overproduce NOS1AP. When the concentration of the protein rose in a particular type of heart cell called a cardiomyocyte, the cells' electrical properties changed in a way that is similar to the pattern seen in long QT syndrome.

Kapoor notes that 67 percent of the general population carries the NOS1AP-overproducing genetic variant. "We have observed that NOS1AP genetic variants are associated with sudden cardiac death whether or not they affect a particular person's QT interval, raising the risk by about 40 percent," he says. Chakravarti notes that the results also add to scientific understanding of how the heart and QT interval work knowledge with far-reaching implications. For example, many drugs developed for noncardiac conditions have turned out to temporarily lengthen QT interval, a side effect that only turns up after much time and money are spent on drug development. By better understanding regulation of the QT interval, researchers would be better able to predict what types of drugs could affect it.

Continue reading here:
Quantity, not quality: Risk of sudden cardiac death tied to protein overproduction

Halfcut - Blunts to Ashes feat. King,Genetics(seven G) Unknown Mizery
Produced by Home Brewed Release: From Dungeons To Rooftops (2014) Nocturne Records http://halfcut.bandcamp.com/album/from-dungeons-to-rooftops https://www....

By: rastaRoss420

Read more from the original source:
Halfcut - Blunts to Ashes feat. King,Genetics(seven G) & Unknown Mizery - Video

The Sims 3: Perfect Genetics Challenge- {Part 7} Talented Toddlers!
Read Me. We spend the entire day teaching the triplets to walk, talk and use the potty! Also, Aden complains about his noisy siblings... a lot. Origi...

By: Moar Sims

Visit link:
The Sims 3: Perfect Genetics Challenge- {Part 7} Talented Toddlers! - Video

The Sims 3: Perfect Genetics Challenge - Ep. 2 1/2

By: simsiguess

More here:
The Sims 3: Perfect Genetics Challenge - Ep. 2 1/2 - Video

The Sims 3 | Perfect Genetics Challenge Part 5: Adios Darren!
In this part, we befriend another man and say bye to lesbian Darren! Backstory: "Once upon a time, the Mighty Player sent a Sim to live in the world where all its creations were living happily....

By: simplyapril

Here is the original post:
The Sims 3 | Perfect Genetics Challenge Part 5: Adios Darren! - Video

Chernobyl TGA genetics
Cali prop 215 medical cannabis collective.

By: xclucifer

Read more:
Chernobyl TGA genetics - Video

How Spouses Are Genetically Similar
Opposites attract... right? Not according to new research! Join Tara as she discusses how most couples are genetically similar, and lists out a few theories as to why this is! Read More: Couples...

By: DNews

See original here:
How Spouses Are Genetically Similar - Video

BEYOND THE BUBBLE: 10 Years of Gene Therapy
10 minute documentary/feature created as my end of year project for my Masters course in TV Journalism at Nottingham Trent University. Made by David Sykes on 15/07/11. Copyright Nottingham...

By: David Sykes

See the original post:
BEYOND THE BUBBLE: 10 Years of Gene Therapy - Video

AChildrens Hospital of Philadelphia spinout with the potential to be the first to win U.S. FDA approval of a gene therapy is now funded through the rest of development of its lead treatment for inherited blindness.

Spark Therapeutics is in the middle of a Phase 3 clinical trial that will determine whether the gene therapy its developed can successfully restore some vision to people with rare degenerative eye diseases caused by mutations in the RPE65 gene. Theres currently no treatmentavailable for these diseases.

To allow Spark to continue that study and prepare for commercialization, the company has just closed an oversubscribed $72.8 million Series B financing. Investors including Sofinnova Ventures, Brookside, Deerfield, Rock Springs Capital, T. Rowe Price, Wellington and CHOP participated.

Developed at CHOPs Center for Cellular and Molecular Therapeutics, the therapy uses a neutralized virus as a vehicle to deliver a function gene to targeted cells in the eye. Once there, it enables production of a critical protein thats missing as a result of a mutation and causes vision loss.

In earlier studies, the company reported that some children who were nearly blind as the result of a RPE65 mutation were able to recognize faces and walk without aid after receiving the treatment.

One major difference between Sparks approach and others under development is that gene therapy has the potential to be a one-time, curative treatment, rather than a treatment patients would need to take for life, said CEO Jeffrey Marrazzo in an email.

The current Phase 3 open-label, randomized, controlled study includes 16 patients who are receiving the therapy through a subretinal injection and eight patients in the control arm. Theyre being monitored for improvements to orientation, mobility, navigational ability and performance on vision tests.

Marrazzo said data is expected in 2015.

In addition to the lead therapy, funding will also support growth in Sparks other gene therapy programs in hemophilia B and other rare diseases.

Although the concept of gene therapy has been around for decades, its only recently advanced to the point where regulatory agencies are acknowledging it as safe and effective enough to approve for sale. A number of companies including Amgen, BlueBird Bio and Advantagene are working toward U.S. approval for gene therapy treatments for cancer or rare diseases.

Read the rest here:
Spark Therapeutics late-stage gene therapy for inherited blindness takes a $73M step forward

AUTOLOGOUS Adipose Stem Cells

Stem Cell Therapy is not a new technology. As a matter of fact it has been around for more that 60 years now. The problem is most people know it as a bone marrow transplant. And well when you finish saying that people are already screaming "That's Painful". A bone marrow transplant essentially extracts stem cells from your own bone marrow and then returns them back to you. It has been used to help people suffering from conditions like Leukemia and Lymph Node Cancer.

How does it work? Stem Cells hone in on "chemokine" signals that are secreted by injury. When they arrive they alert regenerative cells to go to work and repair the damage, or grow tissue.

At birth, the human body has around 80 million active stem cells working. At age 40 we have less than 25 million active stem cells working. Therefore it takes longer for the body to heal and in some cases damage is often ignored. This is the aging or degeneration process of the body.

In 1998 a little known about Bio Tech Company discovered that there was an enormous amount of stem cells in abdominal fat, commonly referred to as Adipose fat. In fact there are about 1-2 million stem cells and regenerative cells in 1 cc of abdominal fat. Bone marrow contains less than 10% of that. The stem cells in the abdomen are in a dormant or inactive state. The challenge lay only in how to activate them.

In early 2000 the problem had been solved. A special separation process was used to isolate stem cells from abdominal fat and a perfected heliotherapy process activated the stem cells. These super-charged stem cells were now ready to go to work healing your body.

Fat Stem Cell Therapy has been used for over a decade now as therapy for a variety of medical problems as well as an alternative to painful cosmetic surgery. Fat Stem Cell Therapy can help patients suffering from medical conditions such as, Osteoarthritis, Pulmonary Disease, and Diabetes Type II, as well as some Cosmetic Procedures like Face Lifts, Breast Augmentation, and Anti-Aging.

Infinite Horizons Medical Center and its association with a leading Bio Tech company are able to deliver these high tech therapies with precision, expertise and a level of care which rivals any in the world. These painless medical procedures uses the clients' own adult stem cells to treat clients' medical problems. The procedures themselves take roughly 3.5 - 7 hours to complete.

The procedure involves extracting autologous adipose stem cells, enriching them, activating the enriched stem cells and finally returning these stem cells back into the clients' body. The procedure only requires a local anesthetic, is 100% safe, 100% effective and there is a 0% chance of rejection. For more detailed information see our procedure page.

Infinite Horizons Medical Center has put together an incredible program for clients in search of medical treatment with fat stem cell therapy for, Pulmonary Disorders, like IPF or COPD, Diabetes Type II and Osteoarthritis. It has also put together special programs with fat stem cell therapy for cosmetic procedures like Anti-Aging, Breast Augmentation and Face Lifts.

Link:
Fat Stem Cell Therapy | Medical Treatments Cosmetic Procedures

Stem Cell Research & Therapy is the major forum for translational research into stem cell therapies. An international peer-reviewed journal, it publishes high quality open access research articles with a special emphasis on basic, translational and clinical research into stem cell therapeutics and regenerative therapies, including animal models and clinical trials. The journal also provides reviews, viewpoints, commentaries and reports.

There has been an error retrieving the data. Please try again.

Immortalization of adipose-derived stromal cells

Immortalized human adipose-derived stromal cells maintain most of their original mesenchymal features, in particular the capability to produce significant amounts of angiogenic factors, with potential advantages for laboratory research and regenerative medicine.

Markers of cellular aging in cultured MSCs

Specific gene markers which distinguish aging multipotent stromal cells (MSCs) grown in culture are identified through gene expression profiling using microarray technology.

WJ-MSC transplantation in diabetes

Treatment with Whartons jelly mesenchymal stem cells (WJ-MSC) can improve metabolic control and beta cell function in patients with type 2 diabetes mellitus.

Cell-based therapy in ophthalmology

Debashish Das and colleagues review the stem cell populations of the eye and their respective functions in cell-based therapy and regenerative medicine in ophthalmology.

Continued here:
Stem Cell Research & Therapy

1st Flight, post Spinal Cord Injury
343 days after my accident I flew from Polipoli on Haleakala, Maui.

By: Justin Boer

Read more from the original source:
1st Flight, post Spinal Cord Injury - Video

CIRM Movie on Diabetes for Viacyte
ViaCyte, Inc., a leader in the emerging field of regenerative medicine, is headquartered in San Diego, California. ViaCyte #39;s innovative product is based on the differentiation of stem cells...

By: Viacyte

Go here to see the original:
CIRM Movie on Diabetes for Viacyte - Video

Hair Transplant Lecture in Brazil: Regenerative Medicine- PRP and ACell
Dallas hair transplant surgeon, Dr. Sam Lam, speaks at the 5th Brazilian Congress on Hair Restoration, held in Maresias, Brazil, on May 23, 2014, on the subj...

By: Samuel Lam

More:
Hair Transplant Lecture in Brazil: Regenerative Medicine- PRP and ACell - Video

The Spanish start-up Aglaris Cell is close to launching onto the market the world's first bioreactor that cultures cell in a fully automated way, without using toxic additives. The device has attracted interest from the University of Oxford and the pharmaceutical giant, Merk.

David Horna, a 33-year-old from Madrid and one of the co-founders of Aglaris Cell, whose offices are located in the Madrid Scientific Park (PCM), is in London this week to meet with investors to secure a second round of funding. Horna, alongside his two partners, Miquel Costa and Manuel A. Gonzlez de la Pea, created the company a little over two years ago with the aim of developing a device that would automate stem cell cultures thereby making advances in the production of 'live' medicines.

As David Horna explained, after four years of intensive research and development, the prototype called Aglaris Facer 1.0, patented in 2012 in Spain and in the process of obtaining its international patent, "is practically ready to be sold on the market."

The idea of developing this device came about when the partners, who worked in various fields of biotechnology, noticed that more and more industries were using cells and tissues in their production processes.

Fully automatic

"We saw that the way live medicines from stem cells were being produced was highly manual, and so we came up with the idea of designing and developing a cell culture bioreactor that could automate the entire process. We believe that the stem cell-based therapies sector is going to expand rapidly in the years to come and will become a very promising business," Horna stated.

He noted that there are other bioreactors on the market and some have been able to automate some of the stages in the process, "but ours is the first in the world to perform all the process stages in a fully automated way."

Until now, an additive called trypsin was usually used in this type of culture, however, trypsin is toxic for cells and removes part of the membrane's proteins. "It has been used up to now because there was no other alternative, but our technology does not need to use this product," Horna said.

"Instead, our development uses an iterative method of cell culture which enables us to completely automate and remove the need for human involvement in the cell separation and washing stages, without using any additives that increase the toxicity level. We have achieved this by using smart surfaces that make cell adhesion and de-adhesion possible depending on changes in the environment," the co-founder explained.

He also adds that "we are currently finalising the developments that also make it possible to use the same device to produce genetically-modified cell lines for cellular reprogramming and gene therapies." These advances build on the work Horna undertook for his thesis on smart surfaces at the Spanish National Centre for Cardiovascular Research (CNIC) and the Sarri Institute of Chemistry (IQS) which was published in the 'Advanced Healthcare Materials' journal.

View post:
Packaged batches of stem cells for regenerative medicine

Dr. J Off Air - SVF Stem Cell Therapy Informational Video
http://www.innovationsstemcellcenter.com Call: 214.420.7970 If you are considering stem cell therapy, you need to watch this video prior to your consultation. Facebook: https://www.facebook.com/i...

By: dallasdrj

Link:
Dr. J Off Air - SVF Stem Cell Therapy Informational Video - Video

(PRWEB) May 26, 2014

The report Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020 analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World (RoW).

Browse 57 market data tables 32 figures spread through 196 Slides and in-depth TOC on Stem Cell Therapy Market. http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html

Early buyers will receive 10% customization on report.

The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. In addition, based on the therapeutic applications, the global stem cell therapy market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others.

Inquire before buying at http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=48.

This report studies the global stem cell therapy market over the forecast period of 2015 to 2020.The market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020.

Download PDF brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=48.

A number of factors such as increasing funding from various government and private organizations, growing industry focus on stem cell research, and rising global awareness about stem cell therapies through various organizations are driving the growth of the global market. In addition, increasing funding for new stem cell lines, development of advanced genomic methods for stem cell analysis, and rising approvals of clinical trials for stem cell therapy are other factors that are propelling the growth of the market.

However, factors such as lack of required infrastructure, ethical issues related to embryonic stem cell, and difficulties related with the preservation of stem cell are restraining the growth of the market.

Go here to read the rest:
Stem Cell Therapy Market Worth $330 Million in 2020 - New Report by MarketsandMarkets

A new Israeli company is using the natural process of cell death to help people undergoing transplants of all kinds live longer. This counterintuitive approach is the vision of Cellect and could radically change the way people with leukemia manage their disease.

Stem cells hold the promise to eradicate cancer and other devastating diseases. But one of the biggest bottlenecks for clinicians and researchers is getting enough stem cells in a blood sample to use in transplantation.

If too many of the donors regular body cells are left in the sample, a patient undergoing a bone-marrow transplant will probably suffer an immune reaction, which can be deadly. In fact, about half of all bone-marrow transplants lead to graft vs. host disease, requiring a lifetime of immunosuppressant drugs.

A new approach to harvesting stem cells is required, says Dr. Shai Yarkoni, a medical doctor, biomed expert and co-founder and CEO of Cellect.

Stem cells are defined not by how they look but what they can do. So my partner, Dr. Nadir Askenasy also a physician, a chemist and a genius came up with an intuitive approach for how we should select them from a sample for transplantation, says Yarkoni in an interview with ISRAEL21c.

Off-the-shelf, cheaper, faster

Several companies, such Miltenyi Biotec in Germany, make tools to cull stem cells from donor blood. But the process is expensive, about $50,000 per transplant, and requires three days of work by skilled personnel. Worse, the current technology still leaves a significant amount of body cells behind or alternatively, too few stem cells.

Thousands of companies and millions of researchers know what they can do with stem cells, but the raw material is the critical issue, Yarkoni says. How do you get enough stem cells to start the treatment?

Cellects stem-cell selection kit, a unique medical device originally conceived by Askenasy about a decade ago, could accomplish the task more effectively, and for a fraction of the cost.

The only tool thats needed is a biological hood, and these can be found even in developing countries. The process takes less than 10 hours and its simple to do, based on the natural process of cell death (apoptosis).

Read more:
Israeli stem-cell technology targets leukemia | ISRAEL21c